Home > Research > Publications & Outputs > Patients' costs associated with seeking and acc...

Research

Links

Text available via DOI:

View graph of relations

Patients' costs associated with seeking and accessing treatment for drug-resistant tuberculosis in South Africa

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

Patients' costs associated with seeking and accessing treatment for drug-resistant tuberculosis in South Africa. / Ramma, L; Cox, H; Wilkinson, L et al.
In: International Journal of Tuberculosis and Lung Disease, Vol. 19, No. 12, 2015, p. 1513-1519.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Ramma, L, Cox, H, Wilkinson, L, Foster, N, Cunnama, L, Vassall, A & Sinanovic, E 2015, 'Patients' costs associated with seeking and accessing treatment for drug-resistant tuberculosis in South Africa', International Journal of Tuberculosis and Lung Disease, vol. 19, no. 12, pp. 1513-1519. https://doi.org/10.5588/ijtld.15.0341

APA

Ramma, L., Cox, H., Wilkinson, L., Foster, N., Cunnama, L., Vassall, A., & Sinanovic, E. (2015). Patients' costs associated with seeking and accessing treatment for drug-resistant tuberculosis in South Africa. International Journal of Tuberculosis and Lung Disease, 19(12), 1513-1519. https://doi.org/10.5588/ijtld.15.0341

Vancouver

Ramma L, Cox H, Wilkinson L, Foster N, Cunnama L, Vassall A et al. Patients' costs associated with seeking and accessing treatment for drug-resistant tuberculosis in South Africa. International Journal of Tuberculosis and Lung Disease. 2015;19(12):1513-1519. doi: 10.5588/ijtld.15.0341

Author

Ramma, L ; Cox, H ; Wilkinson, L et al. / Patients' costs associated with seeking and accessing treatment for drug-resistant tuberculosis in South Africa. In: International Journal of Tuberculosis and Lung Disease. 2015 ; Vol. 19, No. 12. pp. 1513-1519.

Bibtex

@article{280418f6a0d44d89874e2c88ad50ba87,
title = "Patients' costs associated with seeking and accessing treatment for drug-resistant tuberculosis in South Africa",
abstract = "SETTING: South Africa is one of the world's 22 high tuberculosis (TB) burden countries, with the second highest number of notified rifampicin-resistant TB (RR-TB) and multidrug-resistant TB (MDR-TB) cases.OBJECTIVE: To estimate patient costs associated with the diagnosis and treatment of RR-TB/MDR-TB in South Africa.DESIGN: Patients diagnosed with RR-TB/MDR-TB and accessing care at government health care facilities were surveyed using a structured questionnaire. Direct and indirect costs associated with accessing RR-TB/MDR-TB care were estimated at different treatment durations for each patient.RESULTS: A total of 134 patients were surveyed: 84 in the intensive phase and 50 in the continuation phase of treatment, 82 in-patients and 52 out-patients. The mean monthly patient costs associated with the diagnosis and treatment of RR-TB/MDR-TB were higher during the intensive phase than the continuation phase (US$235 vs. US$188) and among in-patients than among out-patients (US$269 vs. US$122). Patients in the continuation phase and those accessing care as out-patients reported higher out-of-pocket costs than other patients. Most patients did not access social protection for costs associated with RR-TB/MDR-TB illness.CONCLUSION: Despite free health care, patients bear high costs when accessing diagnosis and treatment services for RR-TB/MDR-TB; appropriate social protection mechanisms should be provided to assist them in coping with these costs.",
author = "L Ramma and H Cox and L Wilkinson and N Foster and L Cunnama and A Vassall and E Sinanovic",
year = "2015",
doi = "10.5588/ijtld.15.0341",
language = "English",
volume = "19",
pages = "1513--1519",
journal = "International Journal of Tuberculosis and Lung Disease",
issn = "1027-3719",
publisher = "International Union against Tubercul. and Lung Dis.",
number = "12",

}

RIS

TY - JOUR

T1 - Patients' costs associated with seeking and accessing treatment for drug-resistant tuberculosis in South Africa

AU - Ramma, L

AU - Cox, H

AU - Wilkinson, L

AU - Foster, N

AU - Cunnama, L

AU - Vassall, A

AU - Sinanovic, E

PY - 2015

Y1 - 2015

N2 - SETTING: South Africa is one of the world's 22 high tuberculosis (TB) burden countries, with the second highest number of notified rifampicin-resistant TB (RR-TB) and multidrug-resistant TB (MDR-TB) cases.OBJECTIVE: To estimate patient costs associated with the diagnosis and treatment of RR-TB/MDR-TB in South Africa.DESIGN: Patients diagnosed with RR-TB/MDR-TB and accessing care at government health care facilities were surveyed using a structured questionnaire. Direct and indirect costs associated with accessing RR-TB/MDR-TB care were estimated at different treatment durations for each patient.RESULTS: A total of 134 patients were surveyed: 84 in the intensive phase and 50 in the continuation phase of treatment, 82 in-patients and 52 out-patients. The mean monthly patient costs associated with the diagnosis and treatment of RR-TB/MDR-TB were higher during the intensive phase than the continuation phase (US$235 vs. US$188) and among in-patients than among out-patients (US$269 vs. US$122). Patients in the continuation phase and those accessing care as out-patients reported higher out-of-pocket costs than other patients. Most patients did not access social protection for costs associated with RR-TB/MDR-TB illness.CONCLUSION: Despite free health care, patients bear high costs when accessing diagnosis and treatment services for RR-TB/MDR-TB; appropriate social protection mechanisms should be provided to assist them in coping with these costs.

AB - SETTING: South Africa is one of the world's 22 high tuberculosis (TB) burden countries, with the second highest number of notified rifampicin-resistant TB (RR-TB) and multidrug-resistant TB (MDR-TB) cases.OBJECTIVE: To estimate patient costs associated with the diagnosis and treatment of RR-TB/MDR-TB in South Africa.DESIGN: Patients diagnosed with RR-TB/MDR-TB and accessing care at government health care facilities were surveyed using a structured questionnaire. Direct and indirect costs associated with accessing RR-TB/MDR-TB care were estimated at different treatment durations for each patient.RESULTS: A total of 134 patients were surveyed: 84 in the intensive phase and 50 in the continuation phase of treatment, 82 in-patients and 52 out-patients. The mean monthly patient costs associated with the diagnosis and treatment of RR-TB/MDR-TB were higher during the intensive phase than the continuation phase (US$235 vs. US$188) and among in-patients than among out-patients (US$269 vs. US$122). Patients in the continuation phase and those accessing care as out-patients reported higher out-of-pocket costs than other patients. Most patients did not access social protection for costs associated with RR-TB/MDR-TB illness.CONCLUSION: Despite free health care, patients bear high costs when accessing diagnosis and treatment services for RR-TB/MDR-TB; appropriate social protection mechanisms should be provided to assist them in coping with these costs.

U2 - 10.5588/ijtld.15.0341

DO - 10.5588/ijtld.15.0341

M3 - Journal article

VL - 19

SP - 1513

EP - 1519

JO - International Journal of Tuberculosis and Lung Disease

JF - International Journal of Tuberculosis and Lung Disease

SN - 1027-3719

IS - 12

ER -